微信小陈
微信小章| 产品名称： | P815 |
|---|---|
| 商品货号： | TS209443 |
| Organism： | Mus musculus, mouse |
| Cell Type： | mast cell |
| Culture Properties： | suspension (some adherent cells) |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | mastocytoma |
| Strain： | DBA/2 |
| Applications： | This cell line is a suitable transfection host. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Genes Expressed： | lysozyme |
| Cellular Products： | lysozyme Ref   Ralph P, et al. Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines. J. Exp. Med. 143: 1528-1533, 1976. PubMed: 1083890 |
| Comments： | P815 cells phagocytose latex beads but not zymosan or BCG. They do not function in antibody dependent cell mediated cytotoxicity. Growth of the cells is not inhibited by dextran sulfate, LPS or PPD. Tested and found negative for ectromelia virus (mousepox). |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 105 cells/mL and maintain between 1 X 105 and 1 X 106 cells/mL. Adherent cells can be recovered by scraping.
Medium Renewal:xa0Every 2 to 3 days |
| Cryopreservation： | culture medium 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37°C |
| Name of Depositor： | P Ralph |
| Deposited As： | Mus musculus |
| References： | Ralph P, et al. Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines. J. Exp. Med. 143: 1528-1533, 1976. PubMed: 1083890 Ralph P, Nakoinz I. Antibody-dependent killing of erythrocyte and tumor targets by macrophage-related cell lines: enhancement by PPD and LPS. J. Immunol. 119: 950-954, 1977. PubMed: 894031 Ralph P, Nakoinz I. Direct toxic effects of immunopotentiators on monocytic myelomonocytic, and histiocytic or macrophage tumor cells in culture. Cancer Res. 37: 546-550, 1977. PubMed: 318922 Ralph P, Nakoinz I. Lipopolysaccharides inhibit lymphosarcoma cells of bone marrow origin. Nature 249: 49-51, 1974. PubMed: 4208429 Ralph P, et al. Lymphosarcoma cell growth is selectively inhibited by B lymphocyte mitogens: LPS, dextran sulfate and PPD. Biochem. Biophys. Res. Commun. 61: 1268-1275, 1974. PubMed: 4616699 Lundak RL, Raidt DJ. Cellular immune response against tumor cells. I. In vitro immunization of allogeneic and syngeneic mouse spleen cell suspensions against DBA mastocytoma cells. Cell. Immunol. 9: 60-66, 1973. PubMed: 4270287 Plaut M, et al. Studies on the mechanism of lymphocyte-mediated cytolysis. IV. Specificity of the histamine receptor on effector T cells. J. Immunol. 111: 389-394, 1973. PubMed: 4123976 Schmidt W, et al. Cell-free tumor antigen peptide-based cancer vaccines. Proc. Natl. Acad. Sci. USA 94: 3262-3267, 1997. PubMed: 9096381 Gonzalez Armas JC, et al. DNA immunization confers protection against murine cytomegalovirus infection. J. Virol. 70: 7921-7928, 1996. PubMed: 8892915 |